Subject Index

Absorbance spectrum of CDS, 317
ADC. *See* Arginine decarboxylase
Adipocytes, binding sites in, 383, 385-389, 398-400
ADP, potassium channels, and imidazolines, 255-259
Adrenal glands, 23, 163
Adrenal medulla, bovine, clonidine and idazoxan binding in, 421
Adrenergic receptors, 1-5, 222-238
  and brimonidine, 78-92
Affinity states of I_2-receptors, 44-48
Aganodine, 14
Aging, brain
  and α_{2A}-adrenoceptors, 183-184
  and I_2-imidazoline receptors, 183-185
Agmatine, 4, 8, 23, 158, 171, 175, 258, 295-309, 315, 325-329, 330-333, 340-351, 370, 410, 427, 440-443, 536, 574-578
  and imidazoline receptors in rat carotid body, 440-443
  as clonidine-displacing substance, 536
  renal effects of, 344
Alloxan, diabetes induced by, 377-379
Alpha-1 and -2 adrenergic receptor antagonists, 626
Alpha-1 and -2 adrenoceptor agonism, 593
Alpha-2 adrenergic receptors, 112-124, 196, 222-238, 290-294, 295-309, 315, 385-389, 401, 440-443, 459, 541-550
  and imidazoline receptors, 8-19
  in RVLM and blood pressure, 545-546
  subtypes, 1-5
Alpha-1 adrenoceptors in hypotensive response to noradrenaline, 569
Alpha-2 adrenoceptors, 8-19, 96, 112, 125, 146, 179, 362
  and antiidiotypic antibodies, 146
  and depression, 510
  binding sites in dog kidney, 357-360
  binding sites in rat CNS, 196
  in brain, 179
  in hypotensive response to noradrenaline, 569
Alpha-2 agonists as potential antiglaucoma drugs, 463-482
Alpha-2 autoreceptors, 405
Alpha-2 receptors
  and bulbospinal antinociception pathways, 234
  and bulbospinal cardiovascular pathways, 236
  and imidazoline receptors in hypertension, 531-538
Alpha-methylnorepinephrine, 22
Alphamethyldopa as antihypertensive agent, 531
Alzheimer's disease, brain I_2-imidazoline receptors in, 188-189
Amiloride, 171, 197, 375, 422
Amine oxidase activities in fat cells, 380-394
AMPI, 106-110, 151
  in discriminating binding sites, 151
Anorexia, I_2-imidazoline receptor ligand LSL 60101 in, 494-495
Anti-ligand antibodies, 143-144
Anticlonidine antibodies, immunopurification of serum with, 335-338
Antidepressant drugs, 510, 512
Antiidiotypic antibodies, 144-147
  to study imidazoline receptors, 140-147
Antinociception, bulbospinal, and alpha-2 receptors, 234
Antireceptor antibodies, 143-147
Aorta, rabbit
  α_2-autoreceptor and imidazoline interaction, 414
  imidazoline binding sites in, 410
Appetite, imidazoline receptor function in, 135
Aralkylguanidines. *See* Guanafacine, Guanabenz
Area postrema and I-receptors, 216
Arginine decarboxylase (ADC), 325-329, 330-333
Arrhythmias
  cardiac, imidazoline receptors in, 620-632
  halothane-epinephrine, imidazoline receptors in, 610-616
Artery, pulmonary, presynaptic imidazoline receptors in, 414-416
Association for Research in Vision & Ophthalmology, 465
Astrocytes, 23
Atenolol in hypertension, 673-677
Atipamezole, nonadrenergic binding of, in rat lung, 66-75
ATP, potassium channels, and imidazolines, 255
Autoradiography, 24, 222, 229-234, 447-449
  ligand binding studies, 229-234

radioligand-mediated, 222
Autoreceptors
and RVLM C1 adrenergic neurons, 543
inhibitory, in RVLM and clonidine, 541-550

BDF 6143, 31, 408
Behavior, I-receptors in nuclei subserving, 217
2-BFI, 127, 129, 133-134
β-cells
pancreatic, imidazoline binding site in, 152-156, 361-371
potassium channels in, blocked by imidazolines, 243
Binding assays, 23, 96, 163-168
Biphasic competition curves, 44
Blood pressure. *See also* Hypertension
and α_2-adrenoceptor/I receptor drugs, 203
and 2,6-dimethyl clonidine, 98
and brimonidine, 80
and clonidine, 451-452, 545-546
and I_1 agents, 647-651
and I_1-imidazoline receptors, 660-661
and moxonidine, 451-452, 459
Body temperature and clonidine, 35
Bovine adrenal chromaffin cells, 12
Bovine ventrolateral medulla, 10, 96, 285
Brain. *See also* Cerebral cortex
α_2-adrenoceptors in, 179
and arginine decarboxylase, 325-329
and *in situ* hybridization, 225
glial fibrillary acidic protein in, and imidazoline, 486
idazoxan binding to, 178-179, 523-524
imidazoline binding sites in, 140-143, 149-152, 523-524
imidazoline receptors in, 169-171, 178-190, 213, 217, 407-410, 506-508
and suicide, 520-522
in depression and suicide, 189-190
nonadrenergic rilmenidine binding in, 194-204
signal transduction in, and rilmenidine, 290
Brimonidine responses in rabbits and monkeys, 78-92
Bromoxidine, 25
Brown adipose tissue (BAT), I_1 imidazoline binding site in, 398
BU224, 127, 384
BU239, 2, 127
BVLM. *See* Bovine ventrolateral medulla

C1 adrenergic neurons, α_{2A}-autoreceptors, and clonidine, 543
Calcium
channels and 2-(4'-isothiocyanatobenzyl), 283-285
efflux, 37
secretion inhibited by imidazolines, 245
signal, intracellular, and imidazoline, 161
Calcium-activated K^+ transport inhibited by clotrimazole, 287-289
Cardiac arrhythmias, imidazoline receptors in, 620-632
Cardiovascular pathways, bulbospinal, and alpha-2 receptors, 236
Cardiovascular response
to clonidine in denervated rats, 570-572
to noradrenaline, 566-569
Carotid body
I_1-imidazoline sites in, 23
imidazoline receptors and agmatine in, 440-443
Catecholamine release
imidazoline-stimulated, 16
in spontaneously hypertensive rats (SHR), 573-578
CDS. *See* Clonidine-displacing substance
Cells
C1, and clonidine, 541
chromaffin, 30, 157-161, 163, 421-423, 423-426
H1T T15, cirazoline binding to, 112-124
HT29, 2
human platelet, 2
NG108, 2
opossum kidney, 2
PC12, 157-161, 272-281
RIN-5AH, 374-376
RINm5F, 249
Central nervous system
I-receptor binding protein in, 208-218
imidazoline receptors in, 490-492
in essential hypertension, 679-690
rat, rilmenidine binding sites in, 196-197
Cerebral cortex
binding sites in, 149-152
imidazoline receptors in, 407-410
CHAPs-solubilized receptors, 68, 170
Charybdotoxin and potassium channel inhibition, 264
Chromaffin cells
and imidazolines, 423-426
imidazoline binding sites on, 157-161, 163
radioligand binding to, 421-423
Cimetidine, 22
Cirazoline, 12, 22, 106-108, 112-124, 149-152, 171, 272-281, 381, 406, 408, 487

Clonidine, 4, 9, 22, 57, 62, 74, 96, 100, 164-165, 204, 216, 272-281, 340-351, 377-379, 398, 401, 421, 436-438, 463-482, 497-500, 501-504, 510, 570-572, 573-578
and brain, 510
and hypertension, imidazoline receptors in, 532-538
and idazoxan binding sites in brain, 523-524
and locus coeruleus noradrenergic neurons, 501-504
antiarrhythmic effects of, 623
antihypertensive action of, 463-482, 531-538
cardiovascular responses to, in denervated rats, 570-572
in alloxan-induced diabetes in rats, 377-379
in hypertension, 673-677
in obstructive sleep apnea, 446
intrathecal, antinociceptive action of, 497-500
Clonidine binding assays, 96-98, 164-165
Clonidine binding proteins, 528-529
Clonidine-displacing substance, 4, 214-323, 295-309
agmatine as, 536
and imidazoline receptors, 596-599
molecular properties of, 317, 318
Clonidine imidazoline-specific binding, 145
Clonidine-released contractile agents in rat vas deferens, 436-438
Clorgyline, 131, 381
Clotrimazole
calcium-activated K^+ transport inhibited by, 287-289
in sickle cell disease, 262-269
Creatinine clearance, 2,6-dimethyl clonidine in, 98
Cyclic AMP, 4-5, 37
Cyclic GMP in chromaffin cells, effect of clonidine on, 37
Cytochrome P-450 and Gardos channel, 265

2-Deoxyglucose, 132
Depression
and idazoxan, 510
brain I_2-imidazoline receptors in, 189-190
imidazoline receptors in, 130-131, 510-517
platelet α_2-adrenoceptors and I_1 sites in, 512-517
Desipramine (DMI), 131, 512
Detomidine, 48
Dexmedetomidine, 35
Diabetes, noninsulin-dependent, 244
Diacylglycerol, 401
Diazoxide
and insulin secretion in β-cell, 244, 247, 258
and potassium channel activation, 249, 258, 364
3,4-Dihydroxyphenylglycol (DHPG), 680
2,6-Dimethyl clonidine, 96-99
Dipeptides, imidazole-containing, 596-599
DMC. *See* 2,6-Dimethyl clonidine
DOPAC, 132
Dopamine metabolites. *See* DOPAC, HVA
Dorsal root ganglia, RG10 labeling of, 225
Drug discrimination, 136-137
Dynamic interconversion of I_2-sites, 43

Easson-Steadman hypothesis, 592
Efaroxan, 154, 171, 244, 247, 254, 363, 375, 449, 464, 487
arrhythmogenic effect of, 625
Electrolyte transport by moxonidine, 401-404
Endogenous circulating immunoreactive substance, 335-338
Endogenous imidazole-containing dipeptides, 591
Endogenous ligands, 8, 295-309, 335-338
of imidazoline receptors, 295-309, 335-338, 666
Endothelial cells, imidazoline receptors in, 580-588
Epinephrine
and platelet aggregation, 606-608
-halothane arrhythmias, imidazoline receptors in, 610-616
release and imidazolines, 573-578
Epithalamus, I-receptors in, 213
Epithelium of rat vas deferens and clonidine, 436-438
Erythrocytes, sickle, and clotrimazole, 265
Excitatory amino acids and clonidine, 501-504
Excretion, sodium, and imidazoline receptors, 340-351

Fat cells, nonadrenergic imidazoline binding sites in, 380-394
Feeding
behavior, 203
imidazoline receptor function in, 135
Fluoxetine, 512
Fluparoxan, 136
Forebrain, I-receptors in, 213, 217
Frontal cortex, I_2-imidazoline receptors in, and suicide, 520

G-protein, 29, 360
Gamma aminobutyric acid (GABA) and noradrenaline, cardiovascular effects of, 566-569
Gardos channel and potassium depletion in sickle cell disease, 263
Gastric mucosa injury and moxonidine, 433-435
Gastric secretion, moxonidine and, 433
Gel filtration chromatography, 170
GFAP. *See* Glial fibrillary acidic protein
Glaucoma, 78, 463-482
Glial fibrillary acidic protein and imidazoline, 187, 486-488
Glibenclamide, a sulfonylurea drug, 22, 53, 369
Glutamate and imidazoline receptors in rat CNS, 490-492
Gpp(NH)p and idazoxan binding, 182
Guanabenz, 10, 25, 171, 593
Guanfacine, 10, 35, 197
Guanidines. *See* Agmatine, Amiloride, Guanoxan
  α_2-adrenoceptor inhibition by, 405-417
Guanidinium, 366, 426-429
Guanine nucleotides, 23
  regulatory protein, 18
Guanoxan, 385
Guinea pigs
  cardiac arrhythmia in, imidazoline receptors in, 620-632
  I_2-receptors in, 25, 48-54

Halothane-epinephrine arrhythmias, imidazoline receptors in, 610-616
Heart rate and brimonidine, 80
Heterogeneity of I_2-sites, 43
5HIAA, 132
Hindbrain binding, 61
Hippocampal formation, RG10 labeling of, 225
Histadine residues, 102
Histamine, 25, 413
HIT T15 cells, cirazoline binding to, 112-124
Homeotrop allosteric regulation, 52
HPLC chromatography and clonidine-displacing substance, 317
5-HT_3 receptors, inhibitory effects of imidazolines on, 426-429
Human cerebral cortex, binding sites in, 149-152
HVA, 132
Hybridization, *in situ*, 222-238
Hypercapnia, progressive hyperoxic, 452-456
Hyperglycemia, clonidine and, 377-379
Hypertension
  1 kidney-1 clip, 342, 347
  and sleep obstructive apneas, 445-460
  atenolol in, 673-677
  clonidine in, 673-677
  essential, and norepinephrine, 679-690
  I_1 agents in, 642-655
  imidazoline receptor modulators in, 659-668
  imidazoline receptors in, 36, 531-538
  malignant, 635
  moxonidine in, 659-666, 673-677
  primary, 526-527
  rilmenidine in, 634-639, 642-655, 659-666, 673-677
  risk in, 639
Hypotension, ocular, and imidazoline receptors, 463-482
Hypoxia, moxonidine effects on, 456

I-AZIPI, 106-109
[^{125}I]PIC binding assays of I_1 sites, 164-165
I_1 and α_2AR sites and depression, 510-517
I_1- and I_2-receptor antagonists, interaction of, 662
I_1-imidazoline binding sites, 23-34, 98, 100-101, 158, 160
  in rat brown adipocytes, 398-400
I_1-imidazoline receptors, 22-39, 283, 374, 445-460
  and mood disorders, 510-517
  signaling pathways, 37-38
I_2-imidazoline binding sites, 24, 100-102, 158, 160, 172-173, 422
I_2-imidazoline receptors, 43-54, 374-376, 377-379, 506-508
  and glial fibrillary acidic protein, 187, 486
  in depression and suicide, 189-190
  in human brain, 178-190, 189-190, 520-522
  in rat brain and liver, 506-508
  in rat prostate, 174-176
  in suicide victims, 520-522
  ligands, 125-137, 486-488, 494-495
  LSL 60101 as ligand for, 486, 494
I_{2B} binding sites, 360
I_3 sites, 31
Iberiotoxin in potassium transport, 264
IBS. *See* Imidazoline binding sites
Idazoxan, 4, 9, 22, 44, 48, 57, 63, 74, 80, 83, 96, 100, 127, 136, 149-152, 170-171, 172-173, 174-176, 195-196, 197, 254, 296, 316, 358, 363, 389-390, 421, 494, 497-500, 506, 510

and cardiac arrhythmias, 626
and clonidine binding sites
coexistence of, 140-143
in brain, 523-524
and depression, 510
and I_2-imidazoline receptors in suicide victims, 520-522
binding protein, purified, 208
binding sites, 421
and monamine oxidase inhibitors, 389-390
in brain and liver, 506
IGRS. *See* Imidazoline/guanidinium receptive sites
Imidazole-4-acetic acid, 22
Imidazole-containing compounds, 591-601
Imidazoline-containing compounds, 591-601
Imidazoline-preferring receptor (IPR), 463
Imidazolines. *See also* BDF 6100, BDF 6143, Clonidine, Cirazoline, Idazoxan, Moxonidine, Rilmenidine, ST 587, Tolazoline
and antiarrhythmic drugs, 527-528
and insulin release, 153-156, 361-371, 374-376
and ligand-gated ion channels, 420-429
and N1E-115 cells, 426-429
binding sites, 4-5, 100-102, 112-124, 163-168, 272, 287, 357-360, 380-394, 412, 420-429, 591
in brain stem, 523-524
in dog kidney, 357-360
on PC12 and chromaffin cells, 157-161
/guanidinium receptive sites, 106-108
in cardiovascular responses to clonidine, 570-572
in catecholamine release in hypertension, 573-578
insulin secretagogues, 362-363
K^+ channels, and insulin secretion, 243-259
mechanism of sympathoinhibition by, 552-563
metabolic effects of, 664-665
receptor modulators in hypertension, 659-668
receptors, 4, 8-19, 57-64, 66, 100, 125, 140-147, 169-171, 174-176, 194, 236, 248, 290-294, 295-309, 319-321, 325, 330-333, 340-351, 501-504, 580-588, 606-608, 610-616, 661-662
and agmatine in rat carotid body, 440-443
and brimonidine, 78-92
and cardiovascular regulations, 526-529
and hypertension, 531-538
and ocular hypotension, 463-482
and α_2-adrenoceptors in hypertension, 531-538
antiidiotypic antibodies to study, 140-147
binding protein (IRBP) in CNS, 208-218
binding sites, 197
endogenous ligands of, 295-309
in cardiac arrhythmias, 620-632
in cardiovascular responses, 236
in endothelial cells, 580-588
in halothane-epinephrine arrhythmias, 610-616
in rat brain, 169-171
in rat central nervous system, 490-492
in rat prostate, 174-176
in vascular smooth muscle, 580-588
presynaptic, 401
renal effects of, 664-665
Immunoblot analysis, 170
Immunocytochemistry to map I-receptor distribution in CNS, 208
Immunoprecipitation experiments of imidazoline binding sites, 146
In situ hybridization and radioligand-mediated autoradiography, 239
Indomethacin and clonidine, 342, 346
Inositol phosphates, 37
Insulin secretion
imidazoline-mediated, 153-156, 361-371
imidazoline-stimulated, 374-376
imidazolines, and potassium channels, 243-259
Intraocular pressure, 78, 463-482
and pupil diameter measurements, 465
reduced by I_1-imidazoline receptors, 35
Ion channels, ligand-gated, and imidazolines, 420-429
2-(4′-Isothiocyanatobenzyl) imidazoline (IBI), 283
IRBP. *See* Imidazoline receptor binding protein

Kaliotoxin in potassium channel inhibition, 264
K_{ATP} channels in insulin secretion, 361, 374
Kidney
binding, 62-64, 149-152, 172-173, 357-360
I_2-receptors in, 48
imidazoline receptors and sodium excretion in, 340-351

nonadrenergic rilmenidine binding in, 194-204
rilmenidine alters function in, 353-356
Kynurenic acid, 501

Ligand-gated ion channels and imidazolines, 420-429
Lipolysis, regulation of, 392-393
Lipophilicity (log P values) of imidazolines, 425
Liver, I_2-imidazoline receptors in, 506-508
Locus coeruleus, 34, 225
noradrenergic neurons and clonidine, 501-504
RG10 labeling of, 225
Lofexidine, 12, 165
LSL 60101 as I_2-imidazoline receptor ligand, 486-488, 494-495
Lung, atipamezole binding in, 66-75

Medetomidine, 10, 43, 51
Medulla oblongata, I-receptors in, 210
Mesangial cells, 23
Metabolic effects of imidazolines, 665
3-Methoxy-4-hydroxyphenylglycol (MHPG), 680
Methoxyidazoxan. *See* RX821002
Mg^{2+}, 165
Microinjection, 34
Mitochondria, 27, 101, 329
Moclobemide, 136
Molecular mass of CDS, 318
Monkeys, brimonidine responses in, 78-92
Monoamine oxidase, 102, 381
and idazoxan binding, 389-392
and imidazoline receptors, 506-508
in aging brain, and I_2 receptors, 184
inhibitors. *See* Clorgyline, Pargyline, Phenelzine
Mood disorders. *See also* Depression, Suicide
I_1-imidazoline receptors in, 510-517
Moxonidine, 9, 31, 125, 204, 340-351, 401-404, 433-435, 446-447, 448, 573-578, 606-609
and human platelet aggregation, 606-608
and hypertension, imidazoline receptors in, 532-538
and I_1 nonspecific binding, 512
and UK 14304 with yohimbine in rabbits, 556-563
antiarrhythmic effects of, 623-625
in hypertension, 659-666, 673-677
in ouabain-induced cardiac arrhythmia, 620-632
Muscles
upper airway, and obstructive sleep apnea, 446
vascular smooth, imidazoline receptors in, 580-588
Mycelex, 267

N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ), 494-495
$^{22}Na^+$ influx, 14
NAIBS. *See* Nonadrenergic imidazoline binding site
N1E-115 cells, effects of imidazolines on, 426-429
Naphazoline, 25
Negative cooperativity, 48
Nerve growth factor, 23
Nerves
carotid sinus, and moxonidine, 448, 456-458
cranial, and blood pressure, 459
hypoglossal, and I_1-imidazoline receptors, 445-460
phrenic, and I_1-imidazoline receptors, 445-460
Neurons
C1 adrenergic, express RVLM α_{2A}-autoreceptors, 543
locus coeruleus noradrenergic, and clonidine, 501-504
noradrenaline release inhibition in, 405-417
sympathetic preganglionic, 236
Neurotransmitter release, 14
NG108-15 neuroblastoma-glioma, 23
Nicotinic channels inhibited by clonidine and cirazoline, 272-281
Nonadrenergic binding sites, 66, 149-152
Nonadrenergic idazoxan binding sites, 149, 215, 380-394
Nonadrenergic rilmenidine binding in rat brain and kidney, 194-204
Noradrenaline. *See also* Norepinephrine
cardiovascular response to, 566-569
release, 131-132
Norepinephrine
and imidazoline receptors in rat CNS, 490-492
in essential hypertension, 679-690
release and imidazolines, 573-578
Nucleus of solitary tract, 33, 210
Nucleus reticularis lateralis/rostral ventrolateral medulla, 140

Obesity, imidazoline receptor function in, 135
Oligonucleotide probes in *in situ* hybridization in rat brain, 225
Optic nerve, 78

Ouabain, cardiac arrhythmias induced by, 620-632
Oxymetazoline, 197, 464

Pancreas, 23
Pancreatic β-cells
  and imidazolines, 255-259
  imidazoline binding site in, 153-156
Para-aminoclonidine, 9, 57, 74, 195-196, 197, 285, 358, 364, 376, 447, 497-500
Pargyline, 131, 136
Patch-clamp techniques in insulin inhibition, 247
PC12 cells, 23, 272-281, 424
  imidazoline binding sites on, 157-161
Peptide toxins
  Charybdotoxin, 264
  Iberiotoxin, 264
  Kaliotoxin, 264
Pertussis toxin, 341
PGE_2, ELISA assays for, 24
Pharmacology, drug, 673-677
Phenelzine and I_2-imidazoline receptors in brain, 506-508
Phentolamine, 12, 22, 154, 244, 254, 364
Pheochromocytoma cells, 23, 424
Phospholipase A2, 37
Phospholipase C, 37
Photoaffinity ligands, 17
Phthalate density profile, 266
Pituitary hormones and I-receptors, 216
Placenta, human, imidazoline sites in, 319
Plasma membrane, 27, 101, 163
Platelets
  aggregation of, and moxonidine, 606-608
  and depression, 512-517
Polymyxin B in channel gating in insulin-secreting cells, 249
Pons/midbrain, I-receptors in, 210
Positive cooperativity, 48
Potassium, 102, 164, 413
  channels
    activator compounds, 250
    ATP-dependent, and imidazolines, 429
    imidazolines, and insulin secretion, 243-259
Prazosin, 90-91, 568, 626
Preoptic area, effect of clonidine on, 35
Prostaglandins, 37
Prostate, rat, imidazoline I_2 receptor in, 174-176
Protein
  glial fibrillary acidic, and imidazoline, 486-488
  imidazoline binding, 146-147
  imidazoline receptor, immunological detection of, 182
Psychometric studies in man, 663-664

Rabbits
  brimonidine responses in, 78-92
  imidazoline receptors in, and hypertension, 531-538
  imidazolines in, and sympathoinhibition, 552-563
  kidney, binding sites in, 149-152, 172-173
  renal sympathetic reflexes in, and rilmenidine, 534-535
  renal cortex, 102
Radioligand binding studies, 57, 163-168, 497-500
  for I_1-imidazoline sites, 163-168, 497-500
Raphe nuclei, 34
Rat
  alloxan-induced diabetes in, and clonidine, 377-379
  anorexia in, and LSL 60101, 494-495
  brain
    arginine decarboxylase expression in, 325-329, 330-333
    binding of cirazoline to, 112
    imidazoline receptors in, 169-171
    in situ hybridization for examining, 225
    nonadrenergic rilmenidine binding in, 194-204
  carotid body, imidazoline receptors and agmatine in, 440-443
  castration and imidazoline receptor in prostate, 174-176
  central nervous system
    α_2-adrenoceptor binding sites in, and rilmenidine, 196
    imidazoline receptors in, and norepinephrine, 490-492
  clonidine-released agents in vas deferens, 436-438
  denervated, cardiovascular responses to clonidine in, 570-572
  food intake in, and idazoxan, 133
  frontal cortex of, noradrenaline release in, 132
  gastric injury in, and moxonidine, 433-435
  hippocampus, noradrenaline release in, 132
  hypertension in, clonidine and DMC in, 96
  kidney
    imidazoline receptors and sodium excretion in, 340-351
    nonadrenergic rilmenidine binding in, 194-204

liver, imidazoline sites in, 319
lung, atipamezole binding in, 66-75
spinal cord, intrathecal clonidine in, 497-500
spontaneously hypertensive, catecholamine release in, 573-578
Rauwolscine, 15, 80, 96, 98, 112, 204, 316, 358, 406, 411-412, 464
Receptor binding assays, 68
Renal effects of imidazolines, 664-665
Renin and nervous system, 638
Respiration, moxonidine and clonidine effects on, 451-460, 663-664
Riboprobes in *in situ* hybridization studies, 225
Rilmenidine, 9, 31, 125, 194-204, 290-294, 353-356, 399, 446, 573-578, 634-639
and high risk hypertensive patient, 634-639
and hypertension, imidazoline receptors in, 531-538
and renal sympathetic reflexes, 534-535
baroreflex effects of, 535-536
binding, nonadrenergic, in rat brain and kidney, 194
in hypertension, 642-655, 659-666, 673-677
interaction of yohimbine and RX821002 with, 553
renal function and, 353-356
signal transduction in brain and, 290-294
RIN-5AH cells, 374-376
RINm5F cells, 249, 363
Rostral ventrolateral medulla, 22, 163-168
and sympathetic vasomotor tone, 541
hypotensive effect of clonidine in, 545-548
microinjection of imidazolines into, 662
RVLM. *See* Rostral ventrolateral medulla
RX801023, 127
RX801077, 127, 384
RX801080, 368
RX811059, 133, 136
RX821002, 13, 127, 154-156, 179-180, 234, 369, 384, 487, 490, 544
in rillmenidine-treated rabbits, 554
RX821029, 16, 127, 384

S15674, 384
Sedation and alpha$_2$-adrenergic receptors, 35
Serum, immunopurification of, with anticlonidine antibody, 335
Seven transmembrane spanning regions, 17
Sickle cell disease, 262-269
Signal transduction, effect of rilmenidine on, in rat brain, 290
SK&F 10478, 25
SK&F 105854, 80
SK&F 35886, 15
SK&F 86466, 13, 16, 34, 456, 626
in rilmenidine-treated rabbits, 554-556
SKF 525A and idazoxan binding, 508
Sleep, REM, and clonidine, 459
Sleep-related respiratory disturbances and hypertension, 445
Smooth muscle, pharmacology of, and imidazolines, 592
Sodium
channels, ligand- and voltage-gated, 428-429
excretion, 36, 344
transport, 401
Species differences in imidazoline affinities, 25, 58
Spectrometry, plasma desorption mass (PDMS), for measuring CDS, 319
Spinal cord, I-receptors in, 210, 497-500
SRRD. *See* Sleep-related respiratory disturbances
Striatum, RG10 labeling of, 225
Suicide and I_2-imidazoline receptors in brain, 189-190, 520-522
Sulfonylurea drugs, antidiabetic, 250
Sympathetic nervous system in hypertension, 659-668, 679-690
Sympathetic tone reduced by moxonidine and clonidine, 627-632
Sympathoinhibition by imidazolines, 552-563

Tail flick reflex and spinal antinociception, 497-500
Thalamus, I-receptors in, 213
Tizanidine, 9
Tracheal epithelial cells, electrolyte transport in, 401-404
Transgenic mouse model for sickle cell disease, 266
Transmembrane signaling pathway, 23
Tranylcypromine, 381, 390, 506
Trypsin in sulfonylurea blocked potassium channels, 253

UK 14,304, 14, 368, 381, 464, 591
and moxonidine with yohimbine in rabbits, 556-563
in rilmenidine-treated rabbits, 554-556
UK-14,304-18. *See* Brimonidine
Ultraviolet spectrum of CDS, 322
Urine flow, and α_2-adrenoceptors and imidazoline receptors, 348

V2 vasopressin receptor antagonism, 342-344, 349
Vein, saphenous, and presynaptic imidazoline receptors, 416
Ventrolateral medulla (VLM), 10, 96, 285, 476-478

Xylazine, 593

Yohimbine, 16, 22, 62, 487, 497-500, 552-563
in rilmenidine-treated rabbits, 553-554

Index of Contributors

Alemany, R., 486-489, 506-509
Alper, S., 287-289
Alper, S. L., 262-271
Angel, I., 112-124
Arbilla, S., 112-124
Armsby, C. C., 262-271, 287-289
Artiga, O., 494-496
Atlas, D., 314-324

Bakthavachalam, V., 106-111
Belcourt, A., 335-339, 523-525, 526-530
Bennai, F., 140-148, 335-339, 526-530
Beuzard, Y., 262-271
Bönisch, H., 420-432
Bousquet, P., 140-148, 149-152, 335-339, 523-525, 526-530
Bramwell, S., 290-294
Brasili, L., 149-152
Bricca, G., 335-339, 523-525
Brown, C. A., 153-156, 361-373
Brown, C. M., 591-605
Brugnara, C., 262-271, 287-289
Burke, J., 78-95
Bylund, D. B., 1-7

Campbell, W. R., 463-485
Caricati-Neto, A., 436-439
Carpéné, C., 380-397
Cedó, M., 494-496
Celuch, S. M., 566-569
Chan, S. L. F., 153-156, 361-373
Christen, M. A., 659-672
Collins, L. A., 22-42, 445-462
Combes-George, M., 398-400
Costuleanu, M., 377-379
Coupry, I., 287-289
Cox, H. S., 679-694

Dagerlind, A., 222-242
Daly, C. J., 591-605
Darkwa, F. K., 340-352
De Franceschi, L., 262-271
Dendorfer, A., 157-162
Dominiak, P., 157-162, 573-579
Dontenwill, M., 140-148, 149-152, 335-339, 523-525, 526-530
Dreshaj, I. A., 445-462
Dubar, M., 642-658
Dunne, M. J., 243-261

Ehrhardt, J. D., 149-152
Elde, R., 222-242
Elliott, H. L., 673-678
Ernsberger, P., 22-42, 96-99, 163-168, 283-286, 401-404, 445-462
Erokwu, B., 445-462
Escribá, P. V., 169-171, 178-193, 520-522
Esler, M. D., 679-694
Evans, R. G., 357-360

Feldman, J., 335-339, 526-530
Feller, D., 283-286
Felsen, D., 174-177
Ferrier, C., 679-694
Filip, C., 377-379
Fink, K., 405-419
French, N., 125-139

García, M. C., 566-569
García-Sevilla, J. A., 169-171, 178-193, 486-489, 494-496, 501-505, 506-509, 520-522
Gargalidis-Moudanos, C., 172-173
Glavin, G. B., 433-435
Goiny, M., 490-493
Göthert, M., 405-419, 420-432
Graff, L. M., 22-42, 163-168
Graham, D., 112-124
Graves, M. E., 22-42, 163-168, 283-286
Greney, H., 140-148, 149-152, 523-525, 526-530
Gundlach, A. L., 194-207
Gütting, J., 573-579
Guyenet, P. G., 541-551

Halaris, A., 510-519
Hamilton, C. A., 57-65
Handley, S., 125-139
Haque, M., 374-375
Harding, E. A., 243-261
Haüser, W., 573-579
Haxhiu, M. A., 445-462
Hayashi, Y., 610-619
Haynes, J. M., 357-360
Head, G. A., 531-540
Herrera-Marschitz, M., 490-493
Hescheler, J., 272-282
Hieble, J. P., 8-21
Hökfelt, T., 222-242
Huangfu, D., 541-551
Hudson, A., 125-139, 380-397
Husbands, S., 125-139

Jackson, H., 125-139
Jaggar, J. H., 243-261
James, R. F. L., 243-261

Jennings, G. L., 679-694
Johnson, G. G., 22-42
Jordan, S., 125-139
Jurkiewicz, A., 436-439
Jurkiewicz, N. H., 436-439

Kaan, E. C., 659-672
Kalff, V., 679-694
Kamibayashi, T., 610-619
Kane, C., 243-261
Kaye, D. M., 679-694
Kelly, M. J., 679-694
Kendall, D., 591-605
Kharlamb, A., 78-95
King, P. R., 194-207
Koh, I. H. J., 436-439
Krautwurst, D., 272-282
Kulkarni, R. N., 374-375
Kuro, M., 610-619

Lafontan, M., 380-397
Lalies, M. D., 125-139
Lambert, G. W., 679-694
Lanier, B., 106-111
Lanier, S. M., 106-111
Laragh, J. H., 634-641
Le Rouzic, M., 112-124
Lei, L., 283-286
Lewis, J., 125-139
Li, G., 295-313, 325-329, 330-334, 440-444
Li, P., 96-99
Liang, R., 243-261
Liedtke, C. M., 401-404
Lione, L., 125-139
London, N. J. M., 243-261
Louis, W. J., 194-207
Löw-Kröger, A., 659-672
Lynch, K. R., 541-551

MacDermot, J., 374-375
MacKinnon, A., 591-605
MacPhee, G., 673-678
Mallard, N., 125-139
Manlapaz, C., 78-95
Marti, L., 380-397
McGrath, C. R., 106-111
McGrath, J. C., 591-605
Meana, J. J., 178-193, 490-493
Meister, B., 222-242
Menargues, A., 486-489, 494-496
Mest, H.-J., 620-633, 659-672
Miller, D., 283-286
Miller, D. J., 591-605
Milner, T. A., 208-221
Miralles, A., 169-171, 178-193
Molderings, G. J., 405-419, 420-432, 659-672
Molines, A., 140-148, 149-152, 335-339
Monroe, P. J., 497-500
Morgan, N. G., 153-156, 361-373
Mory, G., 398-400
Musgrave, I. F., 272-282

Nagadeh, M., 591-605
Nassir, Y., 174-177
Nechad, M., 398-400
Nechifor, M., 377-379
Negru, A., 377-379
Neughebauer, B. I., 377-379
Neumeyer, J. L., 106-111
Nguyen, P., 22-42
Nguyen, Th., 573-579
Nicholas, A. P., 222-242
Nuñez-Vergara, M., 436-439
Nutt, D. J., 125-139

O'Dowd, A., 591-605
O'Dowd, J. J., 591-605
Obach, R., 486-489, 494-496
Olmos, G., 178-193, 374-375, 486-489, 506-509
Ozaita, A., 169-171

Padillo, E., 78-95
Panfilov, V., 673-678
Parini, A., 100-105, 172-173, 287-289, 398-400
Patil, P., 283-286
Penner, S. B., 340-352, 353-356
Pieribone, V., 222-242
Pigini, M., 149-152
Piletz, J. E., 163-168, 510-519
Pillion, G., 642-658
Pimoule, C., 112-124
Pineda, J., 501-505
Pinthong, D., 591-605
Platt, O., 262-271
Potter, D. E., 463-485
Pratt, J., 125-139
Pupo, A. S., 436-439

Raap, A., 620-633
Raasch, W., 330-334
Regunathan, S., 174-177, 208-221, 290-294, 295-313, 325-329, 330-334, 440-444, 580-590
Reid, J. L., 673-678
Reis, D. J., 169-171, 174-177, 208-221, 290-294, 295-313, 325-329, 330-334, 440-444, 520-522, 580-590
Ricci, D., 570-572

Rifai, N., 262-271
Rittenhouse, A., 262-271
Rosin, D. L., 541-551
Ruffolo, R. R., Jr., 8-21
Ruggiero, D. A., 208-221
Ruiz-Ortega, J. A., 501-505
Runde, E., 78-95
Ruppert, K., 420-432

Saadane, N., 262-271
Sastre, M., 178-193, 520-522
Savola, J.-M., 66-77
Scarpello, K. E., 153-156
Schäfer, S. G., 659-672
Scheinin, M., 66-77
Schlicker, E., 405-419
Schultz, G., 272-282
Shan, T., 78-95
Singh, G., 591-605
Sjöholm, B., 66-77
Slavica, M., 282-286
Smith, D. J., 497-500
Smith, D. L., 497-500
Smyth, D. D., 96-99, 340-352, 353-356, 433-435
Squires, P. E., 243-261
Steffen, G., 157-162
Steinberg, M. I., 606-609
Stornetta, R. L., 541-551
Stutzmann, J., 526-530
Suzuki, S., 194-207
Szabo, B., 552-565

Taira, C. A., 570-572
Templeton, A. G. B., 591-605
Teslariu, E., 377-379
Tesson, F., 398-400
Thomsen, P., 620-633
Trudel, M., 262-271
Tsoli, E., 361-373
Turner, A. G., 679-694

Ugedo, L., 501-505
Urban, R., 552-565

Vaughan, E. D., Jr., 174-177

Wanderley, A. G., 436-439
Wang, H., 208-221, 440-444, 580-590
Westbrooks, K. L., 22-42
Wheeler, L., 78-95
Wiest, S. A., 606-609
Wikberg, J. E. S., 43-56
Wilson, V. G., 591-605

Yamatodani, A., 610-619
Yoshiya, I., 610-619
Youngson, C., 440-444, 580-590

Zakieh, N., 22-42